A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modified
RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older
Category & Conditions: Vaccine-related Conditions
Medicine: PF-07252220
ClinicalTrials.gov Identifier (NCT): NCT05540522
Protocol ID: C4781004
Open Plain Language Summary Result:
Click here